4.5 Editorial Material

Past, present and future of the rule of five

期刊

FUTURE MEDICINAL CHEMISTRY
卷 5, 期 7, 页码 745-752

出版社

FUTURE SCI LTD
DOI: 10.4155/FMC.13.61

关键词

-

向作者/读者索取更多资源

Coined in 1997, by Christopher Lipinki et al., the rule of five (Ro5) comprises a set of parameters that determine drug-likeness for oral delivery. The parameters are as follows: no more than five hydrogen bond donors (nitrogen or oxygen atoms with one or more hydrogen atoms); no more than ten hydrogen bond acceptors (nitrogen or oxygen atoms); a molecular mass less than 500 Da; and an octanol water partition coefficient log P no greater than 5. Future Medicinal Chemistry invited a selection of leading researchers to express their views on Lipinski's Ro5, which has influenced drug design for over a decade. Their enlightening responses provide an insight into the current and future role of Ro5, and other rules of thumb, in the evolving world of medicinal chemistry.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Chemistry, Medicinal

Early career research in medicinal chemistry

Jonathan B. Baell

FUTURE MEDICINAL CHEMISTRY (2021)

Article Chemistry, Medicinal

1-Methyl-1H-pyrazole-5-carboxamide Derivatives Exhibit Unexpected Acute Mammalian Toxicity

Sarah Preston, Jose Garcia-Bustos, Liam G. Hall, Sheree D. Martin, Thuy G. Le, Abhijit Kundu, Atanu Ghoshal, Nghi H. Nguyen, Yaqing Jiao, Banfeng Ruan, Lian Xue, Fei Huang, Bill C. H. Chang, Sean L. McGee, Timothy N. C. Wells, Michael J. Palmer, Abdul Jabbar, Robin B. Gasser, Jonathan B. Baell

Summary: A series of novel compounds were synthesized as potent inhibitors of Haemonchus contortus, the parasitic nematode of sheep, showing high selectivity in mammalian cell lines but causing acute toxicity in rodents, possibly due to respiratory inhibition. Additionally, potent cytotoxicity was observed in rat hepatocytes, unrelated to toxicity in respiring cells.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Article Chemistry, Medicinal

Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines

Daniel L. Priebbenow, Mitch Mathiew, Da-Hua Shi, Jitendra R. Harjani, Julia G. Beveridge, Marina Chavchich, Michael D. Edstein, Sandra Duffy, Vicky M. Avery, Robert T. Jacobs, Stephen Brand, David M. Shackleford, Wen Wang, Longjin Zhong, Given Lee, Erin Tay, Helena Barker, Elly Crighton, Karen L. White, Susan A. Charman, Amanda De Paoli, Darren J. Creek, Jonathan B. Baell

Summary: A series of novel 3,3'-disubstituted-5,5'-bi(1,2,4-triazine) compounds with potent in vitro activity against Plasmodium falciparum parasites were recently discovered. The new structure-activity relationship investigation led to the identification of second-generation highly potent antimalarial bis-triazines, with improved in vitro metabolic stability and a fast-killing profile. This new class of orally available antimalarial compounds is of considerable interest.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Article Chemistry, Medicinal

Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-XL and BCL-2

Michael J. Roy, Amelia Vom, Toru Okamoto, Brian J. Smith, Richard W. Birkinshaw, Hong Yang, Houda Abdo, Christine A. White, David Segal, David C. S. Huang, Jonathan B. Baell, Peter M. Colman, Peter E. Czabotar, Guillaume Lessene

Summary: The BCL-2 family of proteins is an important target for anticancer drug development, with inhibitors like ABT-199/vebetoclax showing transformative effects. Developing new validated chemical series for BCL-X-L is desirable.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Article Microbiology

The Novel bis-1,2,4-Triazine MIPS-0004373 Demonstrates Rapid and Potent Activity against All Blood Stages of the Malaria Parasite

Katherine M. Ellis, Leonardo Lucantoni, Marina Chavchich, Matthew Abraham, Amanda De Paoli, Madeline R. Luth, Anne-Marie Zeeman, Michael J. Delves, Fernando Sanchez-Roman Teran, Ursula Straschil, Jake Baum, Clemens H. M. Kocken, Stuart A. Ralph, Elizabeth A. Winzeler, Vicky M. Avery, Michael D. Edstein, Jonathan B. Baell, Darren J. Creek

Summary: Novel bis-1,2,4-triazine compound MIPS-0004373 demonstrates potent in vitro activity against Plasmodium falciparum parasites, with good efficacy against blood and sexually committed ring stage parasites. The compound also shows activity against liver stage parasites in an in vitro P. berghei model, but limited activity against mature gametocytes. In vivo, MIPS-0004373 efficiently clears established P. berghei infection, with efficacy similar to artesunate and chloroquine.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Article Chemistry, Multidisciplinary

Development of 1,2,4-Oxadiazole Antimicrobial Agents to Treat Enteric Pathogens within the Gastrointestinal Tract

Noel P. Pitcher, Jitendra R. Harjani, Yichao Zhao, Jianwen Jin, Daniel R. Knight, Lucy Li, Papanin Putsathit, Thomas Riley, Glen P. Carter, Jonathan B. Baell

Summary: Colonization of pathogenic bacteria in the GI tract is a significant risk factor for healthcare-associated infections. Efforts to develop effective decolonization agents have been largely unsuccessful. This study modified antimicrobial compounds to target bacterial pathogens in the GI tract and identified potential candidates for further development of colon-targeted antimicrobial agents.

ACS OMEGA (2022)

Article Biochemistry & Molecular Biology

Structure-function analysis of the AMPK activator SC4 and identification of a potent pan AMPK activator

Ashley J. Ovens, Yi Sing Gee, Naomi X. Y. Ling, Dingyi Yu, Justin P. Hardee, Jin D. Chung, Kevin R. W. Ngoei, Nicholas J. Waters, Nolan J. Hoffman, John W. Scott, Kim Loh, Katrin Spengler, Regine Heller, Michael W. Parker, Gordon S. Lynch, Fei Huang, Sandra Galic, Bruce E. Kemp, Jonathan B. Baell, Jonathan S. Oakhill, Christopher G. Langendorf

Summary: AMPK is a cellular energy sensor and regulator of energy homeostasis. Activating AMPK shows potential for treating type 2 diabetes and insulin resistance. Recent studies suggest that the ??202??1 isoform combination is primarily responsible for these effects. Structure/function analysis of SC4 activator led to the discovery of MSG010 and MSG011, which show greater potency in activating ??202??1 AMPK compared to MK-8722. These findings guide the development of selective AMPK activators.

BIOCHEMICAL JOURNAL (2022)

Article Chemistry, Medicinal

Discovery of Anti-tubercular Analogues of Bedaquiline with Modified A-, B- and C-Ring Subunits

Lisa Barbaro, Gayathri Nagalingam, James A. Triccas, Lendl Tan, Nicholas P. West, Daniel L. Priebbenow, Jonathan B. Baell

Summary: The clinical use of bedaquiline has been limited due to safety concerns. Recent investigations have found that modification of the B- and C-ring units of bedaquiline can lead to the development of new compounds with potent anti-tubercular activity but improved safety. Concurrent modification of the A-, B-, and C-ring units in bedaquiline variants has been shown to result in compounds with relatively potent anti-tubercular activity and reduced safety issues.

CHEMMEDCHEM (2023)

Article Chemistry, Medicinal

Hit-to-lead optimization of novel phenyl imidazole carboxamides that are active against Leishmania donovani

Nicole McNamara, Eleanor Saunders, Swapna Varghese, Rebecca Zheng, Kaylene Simpson, Devika M. Varma, Monica M. Johnson, M. Shamim Hasan Zahid, Eric M. Bachelder, Kristy M. Ainslie, Joo Hwan No, Dahae Koh, David Shum, Nirmal Das, Binita Patra, Jayasree Roy, Arindam Talukdar, Dipyman Ganguly, Malcolm McConville, Jonathan Baell

Summary: In this study, the structure-activity relationship of a novel hit compound was explored. The compound showed improved potency with low cytotoxicity against human cells, indicating its potential as a treatment for visceral leishmaniasis.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Oncology

Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia

Victoria Y. Ling, Jasmin Straube, William Godfrey, Rohit Haldar, Yashaswini Janardhanan, Leanne Cooper, Claudia Bruedigam, Emily Cooper, Paniz Tavakoli Shirazi, Sebastien Jacquelin, Siok-Keen Tey, Jonathan Baell, Fei Huang, Jianwen Jin, Yichao Zhao, Lars Bullinger, Megan J. Bywater, Steven W. Lane

Summary: This study identifies defective cell cycle arrest as a clinically relevant contributor to chemoresistance in acute myeloid leukemia (AML). Downregulation of CDKN2A is associated with inferior overall survival in AML patients and occurs at relapse. Therapeutic targeting of the G(1)S cell cycle restriction point and promotion of apoptosis can enhance chemotherapy response in AML.

LEUKEMIA (2023)

Article Immunology

The acetyltransferase KAT7 is required for thymic epithelial cell expansion, expression of AIRE target genes, and thymic tolerance

Melanie Heinlein, Luke C. Gandolfo, Kelin Zhao, Charis E. Teh, Nghi Nguyen, Jonathan B. Baell, Yael Goldfarb, Jakub Abramson, Johannes Wichmann, Anne K. Voss, Andreas Strasser, Gordon K. Smyth, Tim Thomas, Daniel H. D. Gray

Summary: The histone acetyltransferase KAT7 plays a critical role in promoting transcription of peripheral tissue genes and regulating immunological tolerance in thymic epithelial cells. Deficiency of KAT7 leads to impaired immunological tolerance and the development of autoimmune diseases.

SCIENCE IMMUNOLOGY (2022)

Article Biochemistry & Molecular Biology

Target 2035-update on the quest for a probe for every protein

Susanne Mueller, Suzanne Ackloo, Arij Al Chawaf, Bissan Al-Lazikani, Albert Antolin, Jonathan B. Baell, Hartmut Beck, Shaunna Beedie, Ulrich A. K. Betz, Gustavo Arruda Bezerra, Paul E. Brennan, David Brown, Peter J. Brown, Alex N. Bullock, Adrian J. Carter, Apirat Chaikuad, Mathilde Chaineau, Alessio Ciulli, Ian Collins, Jan Dreher, David Drewry, Kristina Edfeldt, Aled M. Edwards, Ursula Egner, Stephen Frye, Stephen M. Fuchs, Matthew D. Hall, Ingo Hartung, Alexander Hillisch, Stephen H. Hitchcock, Evert Homan, Natarajan Kannan, James R. Kiefer, Stefan Knapp, Milka Kostic, Stefan Kubicek, Andrew R. Leach, Sven Lindemann, Brian D. Marsden, Hisanori Matsui, Jordan L. Meier, Daniel Merk, Maurice Michel, Maxwell R. Morgan, Anke Mueller-Fahrnow, Dafydd R. Owen, Benjamin G. Perry, Saul H. Rosenberg, Kumar Singh Saikatendu, Matthieu Schapira, Cora Scholten, Sujata Sharma, Anton Simeonov, Michael Sundstrom, Giulio Superti-Furga, Matthew H. Todd, Claudia Tredup, Masoud Vedadi, Frank von Delft, Timothy M. Willson, Georg E. Winter, Paul Workman, Cheryl H. Arrowsmith

Summary: Twenty years after the first draft of the human genome was published, our understanding of the human proteome is still incomplete. The majority of proteins in the human proteome remain uncharacterized, with only a small percentage successfully targeted for drug discovery. Target 2035 aims to bridge this gap by developing new technologies for the entire human proteome by 2035.

RSC MEDICINAL CHEMISTRY (2022)

Article Biochemistry & Molecular Biology

Synthesis and evaluation of pyridine-derived bedaquiline analogues containing modifications at the A-ring subunit

Lisa Barbaro, Gayathri Nagalingam, James A. Triccas, Lendl Tan, Nicholas P. West, Jonathan B. Baell, Daniel L. Priebbenow

Summary: Despite safety concerns, the clinical use of bedaquiline has been limited, prompting research into modifications within the quinoline ring to discover new variants with improved safety profiles. The development of novel synthetic strategies led to the discovery that anti-tubercular activity could be maintained following replacement of the quinoline motif with pyridine heterocycles, potentially opening up new avenues for improved anti-tubercular therapeutics.

RSC MEDICINAL CHEMISTRY (2021)

Review Biochemistry & Molecular Biology

Nuisance compounds in cellular assays

Jayme L. Dahlin, Douglas S. Auld, Ina Rothenaigner, Steve Haney, Jonathan Z. Sexton, J. Willem M. Nissink, Jarrod Walsh, Jonathan A. Lee, John M. Strelow, Francis S. Willard, Lori Ferrins, Jonathan B. Baell, Michael A. Walters, Bruce K. Hua, Kamyar Hadian, Bridget K. Wagner

Summary: Nuisance compounds, which can waste resources and erode scientific trust, are a major obstacle in realizing the full potential of chemical biology. Understanding and addressing these compounds in complex cell-based assays is essential for efficient drug discovery and research.

CELL CHEMICAL BIOLOGY (2021)

Article Chemistry, Multidisciplinary

Personal Accounts of Australian Drug Discovery at the Public-Private Interface

Jonathan B. Baell

Summary: The public-private interface in drug discovery is a dynamic stage that allows for higher risk but more rewarding research. Adequate resourcing is a perpetual challenge, but persistence, optimism, and flexibility can lead to a highly rewarding career. Selected examples in this account support this notion.

AUSTRALIAN JOURNAL OF CHEMISTRY (2021)

暂无数据